GeNeuro
Innovating by targeting the cause of diseases potentially mediated by endogenous retroviruses - multiple sclerosis, certain neuropathies, diabetes, schizophrenia.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 36.0x EV/Revenue | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €5.0m | Private Placement VC | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 180 % | (50 %) | - | - | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (36 %) | (114 %) | - | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 36 % | (114 %) | - | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
GeNeuro, based in Geneva, Switzerland, is a pioneering biotech company focused on developing treatments for neurodegenerative and autoimmune diseases. The company leverages the emerging biology of human endogenous retroviruses (HERVs) to target the root causes of these conditions. GeNeuro's core product, GNbAC1, has shown efficacy in clinical trials for multiple sclerosis (MS), and the company is expanding its platform to address other diseases such as type 1 diabetes and chronic inflammatory demyelinating polyneuropathy (CIDP). GeNeuro operates in the highly specialized biotech market, primarily serving patients with severe neurological and autoimmune disorders. The business model revolves around research and development (R&D) and clinical trials, with revenue generated through partnerships, licensing agreements, and potential future sales of approved therapies. The company is a member of the Swiss Biotech Association and the BioAlps community, underscoring its commitment to innovation and collaboration within the biotech ecosystem.
Keywords: neurodegenerative, autoimmune, endogenous retroviruses, multiple sclerosis, type 1 diabetes, chronic inflammatory demyelinating polyneuropathy, GNbAC1, biotech, Geneva, clinical trials.